Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy

    Authors

    M. Solh; S. Yohe; D. Weisdorf;C. Ustun

    Comments

    Authors: contact us about adding a copy of your work at STARS@ucf.edu

    Abbreviated Journal Title

    Am. J. Hematol.

    Keywords

    ACUTE MYELOGENOUS LEUKEMIA; HIGH-DOSE CYTARABINE; MINIMAL RESIDUAL; DISEASE; MYOSIN HEAVY-CHAIN; STEM-CELL TRANSPLANTATION; RECEPTOR; TYROSINE KINASE; HISTONE DEACETYLASE INHIBITORS; ACUTE MYELOMONOCYTIC; LEUKEMIA; INTERNAL TANDEM DUPLICATION; FETAL LIVER HEMATOPOIESIS; Hematology

    Abstract

    Core binding factor acute myelogenous leukemia (CBF AML) constitutes 15% of adult AML and carries an overall good prognosis. CBF AML encodes two recurrent cytogentic abnormalities referred to as t(8;21) and inv (16). The two CBF AML entities are usually grouped together but there is a considerable clinical, pathologic and molecular heterogeneity within this group of diseases. Recent and ongoing studies are addressing the molecular heterogeneity, minimal residual disease and targeted therapies to improve the outcome of CBF AML. In this article, we present a comprehensive review about CBF AML with emphasis on molecular heterogeneity and new therapeutic options. Am. J. Hematol. 89:1121-1131, 2014. (c) 2014 Wiley Periodicals, Inc.

    Journal Title

    American Journal of Hematology

    Volume

    89

    Issue/Number

    12

    Publication Date

    1-1-2014

    Document Type

    Review

    Language

    English

    First Page

    1121

    Last Page

    1131

    WOS Identifier

    WOS:000345358600013

    ISSN

    0361-8609

    Share

    COinS